ASXC Stock - Asensus Surgical, Inc.
Unlock GoAI Insights for ASXC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $8.58M | $7.09M | $8.23M | $3.17M | $8.53M |
| Gross Profit | $-4,578,000 | $-3,785,000 | $-2,864,000 | $-1,991,000 | $-12,200,000 |
| Gross Margin | -53.4% | -53.4% | -34.8% | -62.7% | -143.0% |
| Operating Income | $-79,468,000 | $-75,679,000 | $-64,619,000 | $-60,389,000 | $-154,575,000 |
| Net Income | $-78,433,000 | $-75,561,000 | $-62,462,000 | $-59,312,000 | $-154,201,000 |
| Net Margin | -914.5% | -1066.2% | -758.8% | -1868.1% | -1807.5% |
| EPS | $-0.31 | $-0.32 | $-0.28 | $-0.85 | $-8.69 |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 16th 2023 | Cantor Fitzgerald | Downgrade | Neutral | - |
| September 8th 2022 | Cantor Fitzgerald | Initiation | Overweight | $1.5 |
Earnings History & Surprises
ASXCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 13, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.07 | $-0.09 | -28.6% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2022 | Nov 10, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2022 | Aug 8, 2022 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2021 | Nov 3, 2021 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q1 2021 | Mar 11, 2021 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $-0.23 | $-0.12 | +47.8% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $-0.38 | $-0.21 | +44.7% | ✓ BEAT |
Q2 2020 | May 14, 2020 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q1 2020 | Mar 16, 2020 | $-0.62 | $-0.83 | -33.9% | ✗ MISS |
Q4 2019 | Nov 12, 2019 | $-1.01 | $-1.17 | -15.8% | ✗ MISS |
Latest News
Frequently Asked Questions about ASXC
What is ASXC's current stock price?
What is the analyst price target for ASXC?
What sector is Asensus Surgical, Inc. in?
What is ASXC's market cap?
Does ASXC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ASXC for comparison